Neoadjuvant Immunotherapy in TNBC and Targeted LND in Breast Cancer: 2023 Best of Breast Conference

Issues in Triple Negative Breast Cancer: 2023 Best of Breast ConferenceПодробнее

Testing and Targeted Therapy in Triple Negative Breast Cancer: 2023 West OncologyПодробнее

Metastatic Triple Negative Breast Cancer: 2023 Best of Breast ConferenceПодробнее

Triple negative breast cancer -follow up | Dr. Narendran Explains! shorts 1Подробнее

Hot Topics in Advanced Breast Cancer: 2023 Best of Breast ConferenceПодробнее

TNBC Current and Emerging Therapeutic Strategies | 2023 Best of Breast ConferenceПодробнее

Testing, Treating, and Targeting Triple Negative Breast Cancer | 2023 West Oncology ConferenceПодробнее

TNBC: immunotherapy in the neoadjuvant settingПодробнее

Lightning Updates | 2023 Best of Breast ConferenceПодробнее

Optimal neoadjuvant and adjuvant therapy for patients with early TNBCПодробнее

What to do in patients with early-stage TNBC who have not achieved a pCR?Подробнее

Targeting Advanced Triple-Negative Breast Cancer | Dana-Farber Cancer InstituteПодробнее

Utilizing neoadjuvant immunotherapies in patients with ER+, HER2- primary breast cancerПодробнее

Enhancing triple negative breast cancer treatment with immunotherapy across all settingsПодробнее

The importance of a biomarker-directed approach in triple-negative breast cancerПодробнее

KEYNOTE-522: 5-year follow-up of pembrolizumab in triple-negative breast cancerПодробнее

Dr. Yee on Neoadjuvant Therapy for Triple-Negative Breast CancerПодробнее

New directions in immunotherapy for improving outcomes in TNBCПодробнее

KEYNOTE-522 Demonstrates Potential for Immunotherapy in Triple-Negative Breast CancerПодробнее